vTv Therapeutics (VTVT) announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes
- Buy Rating for vTv Therapeutics: Promising Potential of Cadisegliatin in Type 1 Diabetes Treatment
- vTv Therapeutics reports Q1 EPS (77c), consensus (81c)
- vTv Therapeutics reports reinitiation of screening in CATT1 Phase 3 trial
- VTVT Upcoming Earnings Report: What to Expect?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue